UNSPSC 51453107: Oxantel pamoate

This classification denotes a pyrantel analog and antinematodal agent with the molecular formula C23H16O6.C13H16N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier UPY1D732T0, chemically known as (e)-m-(2-(1,4,5,6-tetrahydro-1-methyl-2-pyrimidinyl)vinyl)phenol 4,4'-methylenebis(3-hydroxy-2-naphthoate) (1:1) (salt), but more generally known as oxantel pamoate, which bears US NIH Compound Identifier 5281086.

UNSPSC 51453107 Oxantel pamoate is a Commodity code nominally identifying a specific antiparasitic pharmaceutical, but state and local opportunities tagged under this code show no recent activity for oxantel pamoate itself. Instead, the four recent opportunities span medical and pharmaceutical supply categories broadly: Seminole County, Florida procured naloxone and drug deactivation systems; the City of Tampa solicited medical and first aid supplies for fire rescue operations; the Texas Health and Human Services Commission issued a Request for Information on direct-to-manufacturer prescription programs; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) sought generic multi-source pharmaceuticals and over-the-counter products. The issuing-body mix reflects a cross-section of state agencies, county health departments, city fire services, and cooperative purchasing vehicles. This code's tagging does not align with the actual scope of work being executed; the pharmaceutical and medical-supply procurements occurring under it are substantially broader than oxantel pamoate alone.

Geographically, recent activity is scattered across Florida, Texas, Minnesota, and Oregon, with no concentration in any single state. The City of Tampa's IFB for medical and first aid supplies (26P00145) closed March 13, 2026, with an estimated contract value of $700,000 and a small-local-business-enterprise set-aside; Seminole County's IFB for naloxone and drug deactivation systems (IFB60459723LAS) was due July 26, 2023; the Minnesota MMCAP RFP (S1070000015802) for generic pharmaceuticals and OTC products was due March 26, 2026, with a July 1, 2026 effective date; and the Texas HHS Commission's RFI (HHS0017013) closed April 3, 2026 as exploratory market research on direct-to-manufacturer prescription models. Code activity is light and misdirected — the commodity definition does not match the procurement work actually occurring under it, signaling either misclassification at source or a code that is not actively used for targeted pharmaceutical procurement in state and local markets.